OptimizeRx Announces Board Changes in Press Release
Market News

OptimizeRx Announces Board Changes in Press Release

OptimizeRx Corporation (OPRX) has released an update to notify the public and investors about a regulation fd disclosure.

On January 25, 2024, the Company issued a press release announcing changes to its Board. The press release was provided as part of a Current Report and is considered furnished information, not deemed “filed” for regulatory purposes, nor is it subject to the liabilities of specific sections of the Securities Exchange Act of 1934. It is also not to be incorporated by reference into any filings, unless specifically stated.

For further insights into OPRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
Brian AndersonIs OPRX a Buy, Before Earnings?
TheFlyOptimizeRx continues to expand strategic relationship with pharma client
TheFlyOptimizeRx price target lowered to $14 from $17 at RBC Capital
Go Ad-Free with Our App